Next generation in worldwide treatment of infection and disease
The platform is based on the underlying pharmaceutical activity of CarboHydrate Derived Fulvic Acid (CHD-FA). Having a common safety and toxicity profile, with completed Phase 1 studies in humans for both topical and ingested use, CHD-FA is ideally positioned to enter Phase 2 studies for whatever indication efficacy has been demonstrated.
This research has been carried out by a team of scientists at the New Jersey Medical School’s Public Health Research Institute (PHRI), led by Professor David Perlin and funded by the U.S. Congressionally Directed Medical Research Programs (CDMRP), which foster novel approaches to biomedical research in response to the expressed needs of its stakeholders- the American public, the U.S. military, and Congress.
It is our intention to develop and commercialise the use of CHD-FA in the treatment and/or prevention of wound infections, and the evidence base we have built through the PHRI research and other work makes this a compelling proposition in human and animal health, not just because of the demonstrable efficacy but that it could play a major role in the reduction of antibiotic use. Furthermore, as a safe and highly heat stable product, it has the potential to be deployed under a variety of field conditions.
Extensive research, primarily led by Professor Gordon Ramage, Infection and Immunity Research Group, Glasgow Dental School, University of Glasgow has shown that CHD-FA displays broad-spectrum activity against bacterial and fungal biomass, to similar levels as Chlorhexidine (CHX). CHD-FA is safe, organic and non-toxic to epithelial cells making it an attractive option for the development of a topical agent such a mouthwash or denture cleanser to treat microbial oral disease. We are currently developing both mouthwash and denture soak formulations (e.g. there is currently no effective topical antifungal agent in oral healthcare).
Initial research is showing promising results in applications such as the treatment of mastitis in cows, feed additives for higher mineral absorption, infected wounds and others. Early research shows that a prototype CHD-FA product outperforms the leading 3 mastitis teat dip treatments.
New Combination Products
Results from research carried out at the New Jersey Medical School’s Public Health Research Institute (PHRI), the University of Glasgow, Euprotec (Evotec) and others show that CHD-FA in combination with existing antibiotics is highly effective against drug-resistant bacteria. Using an antibiotic to which an organism is resistant but in combination with CHD-FA, the combination energises the antibiotic to kill the organism. This is probably due to dual modes of action of both the antibiotic and CHD-FA.
This provides opportunities to enter clinical trials for the treatment of drug-resistant bugs and establishing new patents for these treatments.
These initiatives are critical to our strategy of focussing a large proportion of our R&D into high-value areas through the development of formulated products but also by establishing CHD-FA as a novel Platform Technology in those areas and attracting interest for further product development.
Our R&D activities also include areas such as Alzheimer’s Disease, feminine hygiene, eczema, sanitizing and disinfectant formulations.